G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
Yasmin Abaza,Juliana E. Hidalgo-Lopez,Srdan Verstovsek,Elias Jabbour,Farhad Ravandi,Gautam Borthakur,Zeev Estrov,Yesid Alvarado,Jan A. Burger,Heather Schneider,Kelly A. Soltysiak,Yue Wei,Hagop M. Kantarjian,Carlos E. Bueso-Ramos,Guillermo Garcia-Manero +14 more
TL;DR: Ruxolitinib was well-tolerated in previously treated lower-risk MDS patients with evidence of NF-kB activation and resulted in low but significant frequency of responses.
Journal ArticleDOI
Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Naveen Pemmaraju,Hagop M. Kantarjian,Joseph D. Khoury,Susan O'Brien,Jorge E. Cortes,Guillermo Garcia-Manero,Elias J. Jabbour,Nitin Jain,Yesid Alvarado,Madeleine Duvic,Phyu P. Aung,Muzaffar H. Qazilbash,C. Cameron Yin,Sergej Konoplev,Keyur P. Patel,Sherry Pierce,Mark Brandt,Marina Konopleva +17 more
TL;DR: Characteristics and long-term outcomes for patients (pts) at the authors' center with median follow-up time now greater than one year are sought, with the most common cause of death being multi-organ failure.
Journal ArticleDOI
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
Kiran Naqvi,Jorge E. Cortes,Raja Luthra,Susan O'Brien,William G. Wierda,Gautam Borthakur,Tapan M. Kadia,Guillermo Garcia-Manero,Farhad Ravandi,Mary Beth Rios,Sara Dellasala,Sherry Pierce,Elias Jabbour,Keyur P. Patel,Hagop M. Kantarjian +14 more
TL;DR: Patients with E255K/V mutation have a poor prognosis, regardless of the stage of the disease at detection, and after a median follow-up of 65 months from mutation detection, 36 patients died.
Journal ArticleDOI
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
Ghayas C Issa,Aram H Bidikian,Sangeetha Venugopal,Marina Konopleva,Courtney D. DiNardo,Tapan M. Kadia,Gautam Borthakur,Elias Jabbour,Naveen Pemmaraju,Musa Yilmaz,Nicholas J. Short,Abhishek Maiti,Koji Sasaki,Lucia Masarova,Sherry Pierce,Koichi Takahashi,Guilin Tang,Sanam Loghavi,Keyur Patel,Michael Andreeff,Kapil N. Bhalla,Guillermo Garcia-Manero,Farhad Ravandi,Hagop M. Kantarjian,Naval Daver +24 more
TL;DR: In this article , the authors showed that the addition of venetoclax to salvage treatment for NPM1-mutated AML is associated with improved outcomes in relapsed or refractory AML.
Journal ArticleDOI
Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML).
Aref Al-Kali,Dan Jones,Jorge E. Cortes,Stefan Faderl,Xue Ao,Guillermo Garcia-Manero,Gautam Borthakur,Marina Konopleva,Mark Brandt,Michael Andreeff,Hagop M. Kantarjian,Farhad Ravandi +11 more
TL;DR: Induction therapy with Sorafenib, Idarubicin, and Cytarabine is effective in reducing the mutated clone in pts with mutated FLT3 but does not universally eradicate it and continuous therapy with sorafenIB in induction may potentially be beneficial in further reducing the leukemic clone.